Table 2.
Crude and adjusted enrollment, pre-systemic therapy cognitive function by tumor characteristics among older patients with non-metastatic breast cancer
| FACT-Cog PCI scorea |
Attention, processing speed, executive functionb |
Learning and memoryb |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Unadjusted | Adjusted | Unadjusted | Adjusted | Unadjusted | Adjusted | |||||||
| Stage | ||||||||||||
| Stage 0/1 | 60.9 (0.5) | p = 0.452 | 61.0 (0.6) | p = 0.171 | −.052 (0.029) | p = < .001 | −.222 (0.033) | p = 0.005 | −.041 (0.037) | p = 0.699 | −.295 (0.042) | p = 0.733 |
| Stage 2/3 | 60.2 (0.8) | 59.7 (0.9) | − .242 (0.047) | − .369 (0.048) | − .069 (0.061) | − .272 (0.061) | ||||||
| HER2c | ||||||||||||
| Negative | 61.2 (0.5) | p = 0.008 | 60.9 (0.6) | p = 0.023 | − .113 (0.028) | p = 0.946 | − .284 (0.034) | p = 0.786 | − .052 (0.035) | p = 0.170 | − .322 (0.042) | p = 0.292 |
| Positive | 57.3 (1.4) | 57.6 (1.4) | − .107 (0.081) | − .262 (0.079) | − .201 (0.102) | − .428 (0.098) | ||||||
| Tumor size | ||||||||||||
| < 2 cm | 61.3 (0.5) | p = 0.024 | 61.2 (0.6) | p = 0.021 | − .063 (0.029) | p = 0.008 | − .238 (0.034) | p = 0.074 | − .038 (0.038) | p = 0.669 | − .301 (0.043) | p = 0.595 |
| 2 + cm | 59.1 (0.8) | 59.0 (0.9) | − .210 (0.046) | − .331 (0.047) | − .068 (0.060) | − .267 (0.059) | ||||||
| Hormone receptor | ||||||||||||
| Positive | 61.0 (0.5) | p = 0.034 | 60.9 (0.6) | p = 0.131 | − .100 (0.026) | p = 0.534 | − .265 (0.031) | p = 0.915 | − .026 (0.033) | p = 0.043 | − .272 (0.039) | p = 0.163 |
| Negative | 58.2 (1.3) | 58.9 (1.3) | − .148 (0.073) | − .257 (0.070) | − .227 (0.093) | − .400 (0.088) | ||||||
| Grade | ||||||||||||
| Low | 61.2 (1.0) | p = 0.562 | 61.7 (1.4) | p = 0.545 | − .039 (0.062) | p = 0.609 | − .140 (0.078) | p = 0.439 | − .003 (0.079) | p = 0.352 | − .096 (0.098) | p = 0.310 |
| Moderate | 60.3 (0.6) | 60.7 (1.2) | − .109 (0.036) | − .224 (0.064) | 0.018 (0.045) | − .122 (0.079) | ||||||
| High | 59.6 (1.1) | 60.1 (1.5) | − .076 (0.064) | − .182 (0.080) | − .117 (0.082) | − .241 (0.100) | ||||||
| Lymph node | ||||||||||||
| Negative | 60.9 (0.5) | p = 0.907 | 60.8 (0.6) | p = 0.946 | − .097 (0.028) | p = 0.588 | − .262 (0.032) | p = 0.528 | − .043 (0.035) | p = 0.990 | − .281 (0.040) | p = 0.805 |
| Positive | 60.8 (1.0) | 60.9 (1.1) | − .133 (0.059) | − .301 (0.060) | − .044 (0.076) | − .300 (0.075) | ||||||
Unadjusted scores for each individual categorical tumor characteristic were calculated from simple linear regression models, with significance testing based on Type III tests. Adjusted cognitive scores for each individual categorical tumor characteristic were controlled for age, race, and recruitment site in linear regression models
Scores on the FACT-Cog perceived cognitive impairment scale range from 0 to 72, with higher scores represent better cognitive function
Z-scores for neurological tests within each domain range from − 3 to + 3, with a mean of 0. A positive score indicates better cognitive performance and a negative score reflects worse than average scores
HER2 positivity was defined as scoring 3 + on HER2 IHC, or tested positive on HER2 FISH, or receiving Herceptin treatment